Shed Expands Access to Foundayo™ Oral GLP-1 for Weight Management
In a significant move toward improving weight management options, Shed, a prominent online health and wellness platform, has recently announced the availability of Foundayo™ (orforglipron), a new oral GLP-1 therapy developed by Eli Lilly and approved by the FDA. This new offering is aimed at providing a needle-free solution for weight management, allowing users to conveniently integrate it into their daily routines without the need for specific meal timing.
Foundayo™ is specifically designed for adults struggling with obesity or those who have weight-related health conditions, intending to complement a reduced-calorie diet and increased physical activity. Key findings from clinical trials reveal that participants using the highest dosage of this medication reported an average weight loss of 12.4% of their body weight over a period of 72 weeks. Such promising results underscore the potential of Foundayo™ as a substantial addition to weight management strategies.
Morley Baker, the CEO of Shed, expressed enthusiasm over this new addition, stating, "Expanding access to therapies like Foundayo reflects our commitment to offering the most complete wellness journey possible." For many patients who have desired the benefits of GLP-1 medications but have been deterred by the necessity of injections, the introduction of Foundayo™ marks a critical advancement.
Shed's platform facilitates a wholly online experience where patients can undertake a comprehensive evaluation and connect with licensed healthcare professionals. If deemed appropriate, these individuals can receive personalized treatment plans, which may incorporate Foundayo™ as part of a more extensive healthcare strategy. The entire process is designed for convenience, with medications shipped directly to the patient’s doorstep.
This launch further enhances Shed’s existing array of GLP-1 health solutions, solidifying the platform's reputation as a comprehensive resource for evidence-based wellness and weight loss care. As patients increasingly prioritize options that simplify their healthcare experiences, Shed’s commitment to providing an easier route to effective treatments is invaluable.
Eligible patients can now access Foundayo™ through Shed by visiting their website at tryshed.com for further details. Shed's mission remains rooted in helping individuals achieve optimal health – physically, mentally, and emotionally – by amalgamating evidence-based treatments with tailored coaching and continuous support from healthcare providers.
It's important to note the safety information associated with Foundayo™. As a prescription medication, it carries potential risks including the possibility of tumors affecting the thyroid, especially for individuals with a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Common side effects such as nausea, diarrhea, and vomiting have been reported, and it should not be used in conjunction with other GLP-1 receptor agonist medications. As with any healthcare decision, consulting a licensed healthcare professional is essential to determine whether Foundayo™ is the right choice for an individual’s health needs.
In conclusion, Shed’s announcement regarding the addition of Foundayo™ as a new oral therapy option for weight management represents a promising leap towards more accessible and manageable healthcare solutions for patients nationwide. This progressive approach could herald a new era of treatment options aimed at achieving long-term wellness in an increasingly health-conscious society.
Foundayo™ is specifically designed for adults struggling with obesity or those who have weight-related health conditions, intending to complement a reduced-calorie diet and increased physical activity. Key findings from clinical trials reveal that participants using the highest dosage of this medication reported an average weight loss of 12.4% of their body weight over a period of 72 weeks. Such promising results underscore the potential of Foundayo™ as a substantial addition to weight management strategies.
Morley Baker, the CEO of Shed, expressed enthusiasm over this new addition, stating, "Expanding access to therapies like Foundayo reflects our commitment to offering the most complete wellness journey possible." For many patients who have desired the benefits of GLP-1 medications but have been deterred by the necessity of injections, the introduction of Foundayo™ marks a critical advancement.
Shed's platform facilitates a wholly online experience where patients can undertake a comprehensive evaluation and connect with licensed healthcare professionals. If deemed appropriate, these individuals can receive personalized treatment plans, which may incorporate Foundayo™ as part of a more extensive healthcare strategy. The entire process is designed for convenience, with medications shipped directly to the patient’s doorstep.
This launch further enhances Shed’s existing array of GLP-1 health solutions, solidifying the platform's reputation as a comprehensive resource for evidence-based wellness and weight loss care. As patients increasingly prioritize options that simplify their healthcare experiences, Shed’s commitment to providing an easier route to effective treatments is invaluable.
Eligible patients can now access Foundayo™ through Shed by visiting their website at tryshed.com for further details. Shed's mission remains rooted in helping individuals achieve optimal health – physically, mentally, and emotionally – by amalgamating evidence-based treatments with tailored coaching and continuous support from healthcare providers.
It's important to note the safety information associated with Foundayo™. As a prescription medication, it carries potential risks including the possibility of tumors affecting the thyroid, especially for individuals with a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Common side effects such as nausea, diarrhea, and vomiting have been reported, and it should not be used in conjunction with other GLP-1 receptor agonist medications. As with any healthcare decision, consulting a licensed healthcare professional is essential to determine whether Foundayo™ is the right choice for an individual’s health needs.
In conclusion, Shed’s announcement regarding the addition of Foundayo™ as a new oral therapy option for weight management represents a promising leap towards more accessible and manageable healthcare solutions for patients nationwide. This progressive approach could herald a new era of treatment options aimed at achieving long-term wellness in an increasingly health-conscious society.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.